Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioPharmaDive" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioPharmaDive for you to read. Along with our medical data and news we also list BioPharmaDive Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharmaDive Companies for you to search.
Drug pairings tested by Merck & Co. and Pfizer proved effective, and could soon compete with Bristol-Myers' combo in metastatic renal cell carcinoma.
With the targeted cancer drug now exclusively held by Bayer, Lilly's buyout of Loxo becomes an $8 billion bet on the promise of the biotech's RET inhibitor.
High price tags and a potential one-time administration have challenged CMS to figure out reimbursement for CAR-T cell therapies.
Pfizer and J&J are already on the market with products for non-metastatic prostate cancer. Bayer aims to compete with its drug darolutamide.
The drugmaker's plans are part of a broad cost-cutting drive aimed at shrinking its spending base amid ongoing challenges in its generics business.
A refile for Viaskin Peanut boosted the company's shares, but rival Aimmune still looks in position to be first to market.
With the FDA's nod, Egaten is now the first approved therapy in the U.S. for an infectious disease caused by parasites found in contaminated food and water.
Erasing the storied biotech brand is part of a major restructuring designed to support AstraZeneca's return to growth and boost R&D productivity.
Announcement of the trials comes as the drugmaker unveiled mid-stage data from testing of several Keytruda combos in the common cancer type.
Acquiring Citoxlab will build out the contract research organization's footprint into Eastern Europe.
While the lost rights would be a hit to Jazz's revenues, the company has a recombinant version of drug that analysts believe could cushion the blow.
The new cuts bring Ironwood's workforce reduction total to about 235 employees over the past year.
A turnaround for Teva has proved elusive, with competitive pressures overshadowing the Israeli drugmaker's deepening push into specialty medicine.
While a long time coming, Mylan's copycat version now looks set to take a bite out of GSK's respiratory drug sales.
Committee experts recommended the FDA approve the depression drug, giving cover for the agency to take a more "flexible" approach in its review.
Trial results showing a strong survival benefit for Merck's Keytruda in renal cancer could help the pharma make further gains on its immuno-oncology rival.
While predicted by many, selonsertib's failure in STELLAR 4 further dims the drug's prospects as a treatment for the fatty liver disease.
A U.S. patent board declined to institute inter partes review of key patents held by Celgene on its multiple myeloma drug.
Strong data in hormone-sensitive prostate cancer could help Pfizer and Astellas as they face a challenger in J&J's Erleada.
The drugmakers will make Praluent available for 60% less than the cholesterol drug's original price, a decision reflective of persistent commercial hurdles.
Regeneron's blockbuster eye drug benefited certain patients with severe diabetic retinopathy, a market the big biotech is eager to break into.
While data came from only three patients, treatment with uniQure's experimental gene therapy led to Factor IX activity levels high enough to reduce bleeding risk.
Long a pioneer in studying microbiome therapies, Seres has run into hurdles that've spurred it to focus resources on a few priority late-stage assets.
The agency will re-inspect a New Jersey manufacturing facility as part of a regulatory resubmission for the company's lead drug candidate.
Esketamine's clinical track record could raise questions about its efficacy, which will be a key topic during a joint advisory committee meeting next week.